{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:44:52Z","timestamp":1767624292037,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10072-022-05870-x","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T08:02:30Z","timestamp":1641888150000},"page":"3823-3830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chronic migraine evolution after 3\u00a0months from erenumab suspension: real-world-evidence-life data"],"prefix":"10.1007","volume":"43","author":[{"given":"Simona","family":"Guerzoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8432-1888","authenticated-orcid":false,"given":"Carlo","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Pensato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Favoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Lo Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Michela","family":"Cainazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina","family":"Cevoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"5870_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Eng J Med 383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Eng J Med"},{"key":"5870_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"5870_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2016.124","journal-title":"Nat Rev Neurol"},{"key":"5870_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD","year":"2016","unstructured":"GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(17)32154-2","journal-title":"Lancet"},{"key":"5870_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0333102415593088","volume":"36","author":"CC Chiang","year":"2016","unstructured":"Chiang CC, Schwedt TJ, Wang SJ, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia 36:371\u2013381. https:\/\/doi.org\/10.1177\/0333102415593088","journal-title":"Cephalalgia"},{"key":"5870_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s40263-021-00818-9","volume":"35","author":"C Sun-Edelstein","year":"2021","unstructured":"Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS Drugs 35:545\u2013565. https:\/\/doi.org\/10.1007\/s40263-021-00818-9","journal-title":"CNS Drugs"},{"key":"5870_CR7","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","volume":"42","author":"MM Cainazzo","year":"2021","unstructured":"Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci 42:4193\u20134202. https:\/\/doi.org\/10.1007\/s10072-021-05105-5","journal-title":"Neurol Sci"},{"key":"5870_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"key":"5870_CR9","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","volume":"42","author":"E De Matteis","year":"2021","unstructured":"De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42:3297\u20133303. https:\/\/doi.org\/10.1007\/s10072-020-05022-z","journal-title":"Neurol Sci"},{"key":"5870_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/03331024211014616","volume":"41","author":"AR Gantenbein","year":"2021","unstructured":"Gantenbein AR, Agosti R, Gobbi C, Flugel D, Schenkin CJ, Viceic D, Zecca C, Pohl H (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 41:1181\u20131186. https:\/\/doi.org\/10.1177\/03331024211014616","journal-title":"Cephalalgia"},{"key":"5870_CR11","doi-asserted-by":"publisher","unstructured":"Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia; 3331024211046617. https:\/\/doi.org\/10.1177\/03331024211046617.","DOI":"10.1177\/03331024211046617"},{"key":"5870_CR12","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6TM) across episodic and chronic migraine. Cephalalgia 31:357\u2013367. https:\/\/doi.org\/10.1177\/0333102410379890","journal-title":"Cephalalgia"},{"key":"5870_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1046\/j.0333-1024.2001.00277.x","volume":"10","author":"D D\u2019Amico","year":"2001","unstructured":"D\u2019Amico D, Mosconi P, Genco S, Usai S, Prudenzano AMP, Grazzi L, Leone M, Puca FM, Bussone G (2001) The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 10:947\u2013952. https:\/\/doi.org\/10.1046\/j.0333-1024.2001.00277.x","journal-title":"Cephalalgia"},{"key":"5870_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s10194-019-1018-8","volume":"20","author":"B Raffaelli","year":"2019","unstructured":"Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U (2019) Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain 20:66. https:\/\/doi.org\/10.1186\/s10194-019-1018-8","journal-title":"J Headache Pain"},{"key":"5870_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14737175.2020.1772758","volume":"20","author":"E DeMatteis","year":"2020","unstructured":"DeMatteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 20:627\u2013641. https:\/\/doi.org\/10.1080\/14737175.2020.1772758","journal-title":"Expert Rev Neurother"},{"key":"5870_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-018-0883-x","volume":"19","author":"MJ Lee","year":"2018","unstructured":"Lee MJ, Lee SY, Cho S, Kang ES, Chung CS (2018) Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 19:53. https:\/\/doi.org\/10.1186\/s10194-018-0883-x","journal-title":"J Headache Pain"},{"key":"5870_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-020-01189-0","volume":"21","author":"R Greco","year":"2020","unstructured":"Greco R, De Icco R, Demartini C, Zanaboni AM, Tumelero E, Sances G, Allena M, Tassorelli C (2020) Plasma levels of CGRP and espression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain 21:122. https:\/\/doi.org\/10.1186\/s10194-020-01189-0","journal-title":"J Headache Pain"},{"key":"5870_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s10194-020-01193-4","volume":"21","author":"G Tringali","year":"2020","unstructured":"Tringali G, Vollono C, Calabresi P, Navarra P (2020) A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. J Headache Pain 21:124. https:\/\/doi.org\/10.1186\/s10194-020-01193-4","journal-title":"J Headache Pain"},{"key":"5870_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11910-010-0175-6","volume":"11","author":"ME Bigal","year":"2011","unstructured":"Bigal ME, Lipton RB (2011) Migraine chronification. Curr Neur Neurosci Rep 11:139\u2013148. https:\/\/doi.org\/10.1007\/s11910-010-0175-6","journal-title":"Curr Neur Neurosci Rep"},{"key":"5870_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/0333102416654883","volume":"37","author":"B Marics","year":"2017","unstructured":"Marics B, Peitl B, Varga A, P\u00e0zm\u00e0ndi K, B\u00e0csi A, N\u00e9meth J, Szilv\u00e0ssy Z, Jancs\u00f2 G, Dux M (2017) Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia 37:581\u2013591. https:\/\/doi.org\/10.1177\/0333102416654883","journal-title":"Cephalalgia"},{"key":"5870_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","volume":"22","author":"Vernieri F, Altamura C, Brunelli N, Maria Costa C, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia C, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group","year":"2021","unstructured":"Vernieri F, Altamura C, Brunelli N, Maria Costa C, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia C, d\u2019Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https:\/\/doi.org\/10.1186\/s10194-021-01247-1","journal-title":"J Headache Pain"},{"key":"5870_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/head.13765","volume":"60","author":"A Alpuente","year":"2020","unstructured":"Alpuente A, Gallardo VJ, Torres-Ferr\u00f9s M, Alavrez-Sabin J, Pozo-Rosich P (2020) Short and mid-term predictors of response to OnabotulinmtoxinA: real-life experience observational study. Headache 60:677\u2013685","journal-title":"Headache"},{"key":"5870_CR23","doi-asserted-by":"publisher","first-page":"18985","DOI":"10.1073\/pnas.1215435109","volume":"109","author":"A Tozzi","year":"2012","unstructured":"Tozzi A, De Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, Bonsi P, Picconi B, Cupini LM, Materazzi S, Geppetti P, Sarchielli P, Calabresi P (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci 109:18985\u201318990","journal-title":"Proc Natl Acad Sci"},{"key":"5870_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0333102418774299","volume":"39","author":"LN Close","year":"2019","unstructured":"Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39:428\u2013434","journal-title":"Cephalalgia"},{"key":"5870_CR25","doi-asserted-by":"publisher","first-page":"647995","DOI":"10.3389\/fneur.2021.647995","volume":"12","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Ornello R, Favoni V, Sacco S, Caponnetto V, Pierangeli G, Pani L, Cevoli S, Guerzoni S (2021) Chronic migraine and medication overuse headache worsening after OnabotulinumtoxinA withdrawn due to the severe acute respiratory syndrome-coronavirus-2 pandemic. Front Neurol 12:647995","journal-title":"Front Neurol"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-05870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-05870-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-05870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T03:46:33Z","timestamp":1653018393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-05870-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5870"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-05870-x","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"6 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Area Vasta Emilia Nord Ethics Committee (protocol number: 50\/2020\/OSS\/AOUMO) and by the Area Vasta Emilia Centro (protocol number:). All procedures were conducted in accordance with the latest version of the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Every subject signed an informed consent to participate in the study and for data publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"CB received travel grants and honoraria from Allergan, Teva, Novartis, and Ely Lilly. VF received honoraria as a speaker or for participating in advisory boards from Ely Lilly, Novartis, and Teva. MMC received travel grants and honorary from Allergen, Novartis, Ibsa, and Ely Lilly. SC received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, and Lundbeck. SG received travel grants and honoraria from Allergan, Teva, Novartis, and Ely Lilly. LP\u00a0is the Chief Scientific Officer of EDRA-LSWR Publishing Company and of Inpeco SA Total Lab Automation Company. In the last year he has been a scientific consultant to AbbVie, USA; BCG, Switzerland; Boehringer-Ingelheim, Germany; Compass Pathways, UK; Johnson & Johnson, USA; Takeda, USA; VeraSci, USA; Vifor, Switzerland. FLC and UP declare they have no conflict of interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}